Pancreatic Cancer Treatment: Modified T Cells Show Strong Anti-Tumor Properties

Pancreatic cancer a death sentence

Pancreatic cancer is a disease with a very poor prognosis. Only a handful of patients are still alive after five years.

German researchers are working on a type of immunotherapy to directly fight tumor cells. The initial results of the research are highly promising.


Pancreas Image Courtesy of Blausen Medical

According to the American Cancer Society, about 60,430 Americans will be diagnosed with pancreatic cancer of those 48,220 people will die from it.

Read Also: Rush University: Opioid Drugs May Increase the Risk of Pancreatic Cancer

If the patient’s condition and the size of the tumors allow, surgery is usually the main means of treating pancreatic cancer. Otherwise, radiation and chemotherapy are used.

German researchers at Ludwig Maximilian University in Munich are taking a different approach, namely immunotherapy. The goal is to use the immune system to attack pancreatic tumors that multiply rapidly. But these tumors are supported and sometimes obscured by a tissue surrounding them, the tumor stroma. This stroma prevents therapeutic molecules from reaching their target, but lymphocytes can bypass this obstacle if they follow the right instructions.

Read Also: Adagrasib a Promising New Treatment for Lung, Pancreatic, Endometrial, Ovarian and Colon Cancers

Attracting lymphocytes to cancer in the pancreas

Researchers have modified mature T cells to carry the CXC type 6 receptor. With this receptor, the cells are directed through the molecule CXCL6, which is secreted by cancer cells in the pancreas. Once they reach their target within the solid tumor tissue, the lymphocytes can destroy the cancerous cells.

After several experiments on mice with pancreatic cancer, the researchers obtained promising results. The modified T cells proved their anti-tumor properties and the survival rate of the animals increased. Of course, the researchers hope to one day see this protocol in a human clinical trial, but they are only at the beginning of the journey.

Read Also: The Latest in Cancer Treatments From Immunotherapies and Vaccines to Nanoparticles


T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours

Related Articles:

Harvard Medical School Develops TOAD, an AI-Based Diagnostic System for Cancers of Unknown Primary Origin

Cancer-Linked Mutation Promotes Growth of Abnormal Blood Vessels in Brain

Promising Clinical Trials for Advanced Lung Cancer That Are Currently Recruiting Patients in the US

Recurrent Urinary Tract Infections May Lead to Bladder Cancer Study Shows

A New Test That Can Detect Endometrial Cancer From Urine and Vaginal Samples Developed by English Researchers



Want to Stay Informed?

Join the Gilmore Health News Newsletter!

Want to live your best life?

Get the Gilmore Health Weekly newsletter for health tips, wellness updates and more.

By clicking "Subscribe," I agree to the Gilmore Health and . I also agree to receive emails from Gilmore Health and I understand that I may opt out of Gilmore Health subscriptions at any time.